CML
Conference Coverage
Depth of molecular response factors into safe TKI withdrawal in CML
Key clinical point: Long-time TKI therapy can be stopped in chronic myeloid leukemia in deep molecular remission.
Conference Coverage
Switch to nilotinib improves deep molecular response in CML
©ASCO/Phil McCarten CHICAGO—Patients with chronic myeloid leukemia (CML) are more likely to achieve a deep molecular response if they switch to...
Conference Coverage
Imatinib appears safe, effective for the long haul
Key clinical finding: Imatinib is safe and effective for treating patients with chronic myeloid leukemia over the course of a decade. Major...
Reviews
Molecular monitoring and minimal residual disease in the management of chronic myelogenous leukemia
News
FDA approves CML drug for home administration
The US Food and Drug Administration (FDA) has expanded the approval of omacetaxine mepesuccinate (Synribo) to include home administration. The...
News
Cell adherence linked to treatment resistance in CML
Credit: UC San Diego Preclinical research in chronic myeloid leukemia (CML) has pointed to a relationship between cell adherence and treatment...
News
Omacetaxine mepesuccinate gets full FDA approval
Credit: Bill Branson The US Food and Drug Administration (FDA) has granted full approval of omacetaxine mepesuccinate (Synribo) for the treatment...
News
Affluence seems to affect CML survival in the UK
Credit: CDC Results of population-based research suggest that financial status may affect survival in patients with chronic myeloid leukemia (CML...
News
Ponatinib back on the market
Ariad Pharmaceuticals, Inc., has begun shipping the drug to Biologics, Inc., its exclusive specialty pharmacy.
News
Out-of-pocket costs hinder adherence to imatinib
Credit: CDC When their share of prescription costs becomes too high, many patients with chronic myeloid leukemia (CML) will skip doses of...